Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

Patwa, Huned; Chaudhry, Vinay; Katzberg, Hans D.; Rae-Grant, Alex; So, Yuen T.

doi:10.1212/wnl.0b013e31824de293

Cited by 222 publications

(164 citation statements)

References 39 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Li et al for their comments regarding our article. 1 As the authors indicate, our findings are consistent with those from other guidelines addressing the same topic, although different methodologies may result in different recommendations. Our analysis is based on the process outlined in the AAN guideline development manual.…”

supporting

confidence: 90%

Evidence-Based Guideline: IV Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Li¹,

Gao²,

Hong³

et al. 2012

Neurology

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 90%

Evidence-Based Guideline: IV Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Li¹,

Gao²,

Hong³

et al. 2012

Neurology

Self Cite

View full text Add to dashboard Cite

“…6 More controversially, consensus guidelines on the use of PLEX in neurologic disease published by the AAN in 2011 suggested there is insufficient evidence for the use of PLEX in acute MG crisis, due to the lack of randomized, placebo-controlled trials. 7 However, many neuromuscular specialists disagree with this assessment, which led to an editorial in response to the guidelines.…”

Section: Plasmapheresis Vs Ivigmentioning

confidence: 99%

Myasthenia gravis

Statland

Ciafaloni

2013

Neur Clin Pract

View full text Add to dashboard Cite

SummaryMyasthenia gravis (MG) is the most common autoimmune disease affecting neuromuscular junction transmission. MG is characterized by muscle weakness that worsens with activity and fluctuates over the course of the day. Involvement of respiratory musculature can lead to life-threatening crisis requiring intensive care unit care. Antibody testing is positive in most patients with MG. Treatment of MG includes short-term symptomatic treatment, chronic immunosuppression, surgical intervention, and immunomodulatory therapies for severe disease or crisis. We review advances in 5 areas relevant to diagnosis and management of MG: the role of IV immunoglobulin vs plasmapharesis in myasthenic crisis and severe disease; the clinical characterization of patients with antibodies to muscle-specific tyrosine kinase receptors; old and new investigational treatments; management of MG in pregnancy; and new confirmatory diagnostic tests. M yasthenia gravis (MG) is the most commonly encountered autoimmune disease of the neuromuscular junction with an estimated worldwide prevalence between 15 and 179 per million people. MG causes fluctuating weakness that worsens with activity and as the day progresses, and ocular weakness, causing ptosis and diplopia.1 In 15% of patients, life-threatening respiratory weakness can occur, called myasthenic crisis. Ocular symptoms are the most common presenting symptoms, with around two-thirds of patients progressing to generalized disease, usually within the first 2 years. The diagnosis is based on clinical history and neurologic examination and confirmed by electrodiagnostic testing and the presence of serum autoantibodies directed at proteins in the neuromuscular junction. The vast majority of patients with generalized MG (;85%) and pure ocular MG (;50%) will have antibodies to the skeletal muscle nicotinic acetylcholine receptor (AChR). An additional 8%-10% of patients with generalized disease have antibodies to muscle-specific tyrosine kinase receptor (MuSK), an enzyme involved in acetylcholine receptor clustering in the synaptic cleft.

show abstract

“…Because of catheters used for IV treatments (IVIG, plasma), and for respiratory support (intubation) especially during attack periods, patients are at risk for infections with resistant microorganisms [4]. Daptomycin -a cyclic lipopeptide, which has been approved as an effective agent in treatment of skin and soft tissue infections, and bacteremia caused by MRSA, has recently been used in clinical practice with success [5].…”

Section: Discussionmentioning

confidence: 99%

Daptomycin Use in MRSA Bacteremia of a Patient with Myasthenia Gravis: A Case Report

Arslan¹,

Karagöz²,

Arslan³

2016

Med-Science

View full text Add to dashboard Cite

show abstract

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

Cited by 222 publications

References 39 publications

Evidence-Based Guideline: IV Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Evidence-Based Guideline: IV Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Myasthenia gravis

Daptomycin Use in MRSA Bacteremia of a Patient with Myasthenia Gravis: A Case Report

Contact Info

Product

Resources

About